Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

April 2018

Column

Counterpoint
Understanding Provider Perceptions Is Key to Utilization and Uptake of CAR-T Therapy
04/17/2018
Bruce A Feinberg, DO
Chadi Nabhan, MD, MBA, FACP
The potential impact of chimeric antigen receptor T-cell (CAR-T) therapies should not be underestimated, nor should their complexity. There is much to consider when reprogramming patients’ own immune cells. As most...
The potential impact of chimeric antigen receptor T-cell (CAR-T) therapies should not be underestimated, nor should their complexity. There is much to consider when reprogramming patients’ own immune cells. As most...
The...
04/17/2018
Journal of Clinical Pathways
Viewpoint
The CAR-T Breakthrough: More Than Just Another Treatment Option
04/17/2018
Winston Wong, PharmD, Editor-in-Chief
The ability to rewire human immune systems to fight cancer is certainly an exciting prospect. With the first 2 chimeric antigen receptor T-cell (CAR-T) therapies approved and over 200 more in clinical trials,...
The ability to rewire human immune systems to fight cancer is certainly an exciting prospect. With the first 2 chimeric antigen receptor T-cell (CAR-T) therapies approved and over 200 more in clinical trials,...
The...
04/17/2018
Journal of Clinical Pathways
Clinical Pathways GPS
Dealing With New Formulary Types: Health System Outpatient Formularies
04/17/2018
Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor
Developers and utilizers of clinical pathways need to understand that formulary systems encompass more than merely a list of medications approved by a managed care organization. These stakeholders should also factor...
Developers and utilizers of clinical pathways need to understand that formulary systems encompass more than merely a list of medications approved by a managed care organization. These stakeholders should also factor...
...
04/17/2018
Journal of Clinical Pathways
Pharma Insights
Economic Assessment of Novel Gene and Cellular Therapies: Beyond Traditional Modeling
04/17/2018
Philip Cyr, MPH
Larry Blandford, PharmD—Column Editor
Various forms of decision health analytic modeling have been used for the last 3 decades to assess potential health economic impact of new therapies. As initial gene and cellular therapies come to market, debate is...
Various forms of decision health analytic modeling have been used for the last 3 decades to assess potential health economic impact of new therapies. As initial gene and cellular therapies come to market, debate is...
...
04/17/2018
Journal of Clinical Pathways
Editor's Page
Working Together to Ensure Patient Access to Clinical Advancements
04/17/2018
Winston Wong, PharmD, Editor-in-Chief
It is an exciting time in oncology care as innovative cellular and gene therapies come to market, with many more to come in the near future. While the promise of these therapies is certainly cause for enthusiasm,...
It is an exciting time in oncology care as innovative cellular and gene therapies come to market, with many more to come in the near future. While the promise of these therapies is certainly cause for enthusiasm,...
It is...
04/17/2018
Journal of Clinical Pathways

Feature

Perspectives
Creating Value in Cancer Care Through Standardized Metrics and Partnerships Between Patient Navigators and Physicians
04/17/2018
Tricia Strusowski, MS, RN
Abstract: While providers and care systems can agree that effective patient navigation programs are essential to positive patient outcomes, there have been no standard metrics that could be used to measure the...
Abstract: While providers and care systems can agree that effective patient navigation programs are essential to positive patient outcomes, there have been no standard metrics that could be used to measure the...
...
04/17/2018
Journal of Clinical Pathways

Insights

Interview
McKesson Specialty Health`s Oncology-Specific EHR: A Model for Advancing Value-Based Care
04/17/2018
JCP Editors
For the second consecutive year, McKesson Specialty Health has received approval from the Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-Based Incentive Payment System (MIPS) program...
For the second consecutive year, McKesson Specialty Health has received approval from the Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-Based Incentive Payment System (MIPS) program...
For...
04/17/2018
Journal of Clinical Pathways
National Comprehensive Cancer Network Annual Conference
04/17/2018
JCP Editors
The National Comprehensive Cancer Network (NCCN) is a nonprofit alliance of 27 leading cancer centers devoted to patient care, research, and education, and is dedicated to improving the quality, effectiveness, and...
The National Comprehensive Cancer Network (NCCN) is a nonprofit alliance of 27 leading cancer centers devoted to patient care, research, and education, and is dedicated to improving the quality, effectiveness, and...
The...
04/17/2018
Journal of Clinical Pathways
Society of Gynecological Oncology Annual Meeting on Women`s Cancer
04/17/2018
JCP Editors
The premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers, the Society of Gynecological Oncology (SGO) contributes to the advancement of...
The premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers, the Society of Gynecological Oncology (SGO) contributes to the advancement of...
The...
04/17/2018
Journal of Clinical Pathways

Department

Research in Review
Research in Review
04/17/2018
JCP Editors
Texas Oncology, Aetna Collaborate to Improve Patient Care Through Clinical Pathways Texas Oncology and Aetna partnered to provide a practice-based program that reduced costs while maintaining adherence to treatment...
Texas Oncology, Aetna Collaborate to Improve Patient Care Through Clinical Pathways Texas Oncology and Aetna partnered to provide a practice-based program that reduced costs while maintaining adherence to treatment...
Texas...
04/17/2018
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Volume 4

View Issue Archive
Editorial Correspondence

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement